These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2357863)

  • 21. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
    Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
    J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the pharmacokinetic and pharmacodynamic interaction between quinidine and nifedipine.
    Bowles SK; Reeves RA; Cardozo L; Edwards DJ
    J Clin Pharmacol; 1993 Aug; 33(8):727-31. PubMed ID: 8408733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinetic evaluation of the propranolol-quinidine combination.
    Fenster P; Perrier D; Mayersohn M; Marcus FI
    Clin Pharmacol Ther; 1980 Apr; 27(4):450-3. PubMed ID: 7357801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
    Lennard MS; Tucker GT; Woods HF
    Clin Pharmacokinet; 1986; 11(1):1-17. PubMed ID: 2868819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of quinidine on the 10-hydroxylation of R-warfarin: species differences and clearance projection.
    Chen Q; Tan E; Strauss JR; Zhang Z; Fenyk-Melody JE; Booth-Genthe C; Rushmore TH; Stearns RA; Evans DC; Baillie TA; Tang W
    J Pharmacol Exp Ther; 2004 Oct; 311(1):307-14. PubMed ID: 15163679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative antiarrhythmic activity of quinidine combined with propranolol and with sotalol.
    Lawson JW; Wojciechowski NJ
    Arch Int Pharmacodyn Ther; 1981 Jan; 249(1):72-86. PubMed ID: 6111984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans.
    Schellens JH; Ghabrial H; van der Wart HH; Bakker EN; Wilkinson GR; Breimer DD
    Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):520-8. PubMed ID: 1934865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical implications of the competitive inhibition of the debrisoquin-metabolizing isozyme by quinidine.
    Caporaso NE; Shaw GL
    Arch Intern Med; 1991 Oct; 151(10):1985-92. PubMed ID: 1681790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
    Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
    Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation.
    Abernethy DR; Barbey JT; Franc J; Brown KS; Feirrera I; Ford N; Salazar DE
    Clin Pharmacol Ther; 2001 Mar; 69(3):96-103. PubMed ID: 11240972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
    Masubuchi Y; Hosokawa S; Horie T; Suzuki T; Ohmori S; Kitada M; Narimatsu S
    Drug Metab Dispos; 1994; 22(6):909-15. PubMed ID: 7895609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of quinidine and propranolol in experimental cardiac arrhythmias in the dog.
    Madan BR; Pendse VK
    Arch Int Pharmacodyn Ther; 1977 Feb; 225(2):287-93. PubMed ID: 849075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Greater quinidine-induced QTc interval prolongation in women.
    Benton RE; Sale M; Flockhart DA; Woosley RL
    Clin Pharmacol Ther; 2000 Apr; 67(4):413-8. PubMed ID: 10801251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Studies on active transport of (E)-10-hydroxynortriptyline in the kidney and brain of rats: effects of propranolol and quinidine.
    Otani K; Kaneko S; Bertilsson L
    Pharmacol Toxicol; 1991 May; 68(5):380-3. PubMed ID: 1946183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males.
    Karbwang J; Davis TM; Looareesuwan S; Molunto P; Bunnag D; White NJ
    Br J Clin Pharmacol; 1993 Mar; 35(3):265-71. PubMed ID: 8471402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A microelectrophysiological analysis of the pharmacodynamic basis for quinidine-propranolol antiarrhythmic potentiation.
    Iansmith DH; Bandura JP; Nash CB
    J Pharmacol Exp Ther; 1981 Dec; 219(3):651-8. PubMed ID: 7299688
    [No Abstract]   [Full Text] [Related]  

  • 37. Inhibition of quinidine-propranolol elevation of the ventricular fibrillation threshold by bilateral stellectomy+vagotomy in the anesthetized dog.
    Lawson JW
    Arch Int Pharmacodyn Ther; 1986 Mar; 280(1):74-83. PubMed ID: 3718083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered?
    Rameis H
    Int J Clin Pharmacol Ther Toxicol; 1985 Mar; 23(3):145-53. PubMed ID: 3997300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of the combination of quinidine and propranolol upon atrial and ventricular automatically in dogs.
    Korte DW; Nash CB
    J Pharmacol Exp Ther; 1978 Feb; 204(2):303-11. PubMed ID: 340642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers.
    Leemann T; Dayer P; Meyer UA
    Eur J Clin Pharmacol; 1986; 29(6):739-41. PubMed ID: 3709620
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.